INS and gestational diabetes: The limitations of this meta-analysis are linked not only to the high variability between the studies in the incidence of requiring additional insulin (especially high in the study of Rowan (18), 46.3%) but also to the high variability in metformin dose, the criteria of GDM’s diagnosis, and the glycemic targets.